Sugi Predict

Sugi Predict / Compounds / SCHEMBL1898024

SCHEMBL1898024

SCHEMBL1898024

O=C(Nc1nnc(-c2ccc(Cl)s2)o1)c1cc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 8/20 0.74
▸ SMN1; SMN2 Q16637 5/20 0.73
▸ LMNA P02545 4/20 0.73
▸ KDM4E B2RXH2 4/20 0.73
▸ MEN1 O00255 4/20 0.73
▸ KMT2A Q03164 4/20 0.73
▸ HTT P42858 2/20 0.73
▸ TDP1 Q9NUW8 2/20 0.73
▸ MAPT P10636 4/20 0.65
▸ ALDH1A1 P00352 3/20 0.65
▸ HPGD P15428 3/20 0.65
▸ GLA P06280 2/20 0.65
▸ HCRTR1 O43613 1/20 0.65
▸ MAPK1 P28482 1/20 0.65
▸ RXFP1 Q9HBX9 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ PPARG P37231 1/20 0.58
▸ NCOA2 Q15596 1/20 0.58
▸ NCOA1 Q15788 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898948 0.86 STAT3 (1.00) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1898646 0.85 STAT3 (0.78) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1899281 0.85 STAT3 (0.78) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1900368 0.84 STAT3 (1.00) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1900917 0.84 STAT3 (1.00) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1900296 0.83 STAT3 (0.79) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1903465 0.80 STAT3 (0.80) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL15015470 0.80 STAT3 (0.88) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL1898628 0.80 STAT3 (0.73) STAT3SMN1; SMN2LMNAKDM4EMEN1
SCHEMBL17717059 0.80 KDM4E (0.75) STAT3SMN1; SMN2LMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218693-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE KABUSHIKI KAISHA YAKULT HONSHA (JP) 2022-07-14 — — US disclosed
EP-3960199-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE Kabushiki Kaisha Yakult Honsha (JP) 2022-03-02 — — EP disclosed
US-20220008409-A1 CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE KABUSHIKI KAISHA YAKULT HONSHA (JP) 2022-01-13 — — US disclosed
EP-3854397-A1 CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE Kabushiki Kaisha Yakult Honsha (JP) 2021-07-28 — — EP disclosed
WO-2020218432-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE 株式会社ヤクルト本社 2020-10-29 — — WO disclosed
US-20170273954-A1 METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS THE UNIVERSITY OF CHICAGO (US) 2017-09-28 — — US disclosed
US-20170273954-A1 METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS THE UNIVERSITY OF CHICAGO (US) 2017-09-28 — — US disclosed
US-9675592-B2 Methods and compositions for bacteria infections THE UNIVERSITY OF CHICAGO (US) 2017-06-13 — — US disclosed
US-9675592-B2 Methods and compositions for bacteria infections THE UNIVERSITY OF CHICAGO (US) 2017-06-13 — — US disclosed
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 — — EP disclosed
US-20160120852-A1 METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) 2016-05-05 — — US disclosed
US-20160120852-A1 METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) 2016-05-05 — — US disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 — — US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 — — US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170273954-A1 METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS SPOUT1, OXA1L, VSIR STAT3 1830/4885SMN1; SMN2 1662/4885LMNA 1893/4885
US-20220008409-A1 CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE JAK2, ROS1, ABL1 STAT3 14/4885SMN1; SMN2 4783/4885LMNA 4862/4885
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885SMN1; SMN2 4492/4885LMNA 4766/4885
US-20220218693-A1 IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE STAT3, PDCD1, CD274 STAT3 1/4885SMN1; SMN2 4442/4885LMNA 4467/4885
US-20160120852-A1 METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS SPOUT1, OXA1L, VSIR STAT3 1830/4885SMN1; SMN2 1662/4885LMNA 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.